New! View global litigation for patent families

WO1996037519A1 - A polysaccharide hydrogel material, a process for its preparation and its use in medicine, surgery, cosmetics and for the preparation of health care products - Google Patents

A polysaccharide hydrogel material, a process for its preparation and its use in medicine, surgery, cosmetics and for the preparation of health care products

Info

Publication number
WO1996037519A1
WO1996037519A1 PCT/EP1996/002270 EP9602270W WO1996037519A1 WO 1996037519 A1 WO1996037519 A1 WO 1996037519A1 EP 9602270 W EP9602270 W EP 9602270W WO 1996037519 A1 WO1996037519 A1 WO 1996037519A1
Authority
WO
Grant status
Application
Patent type
Prior art keywords
hydrogel
according
ml
acid
solution
Prior art date
Application number
PCT/EP1996/002270
Other languages
French (fr)
Inventor
Davide Bellini
Lanfranco Callegaro
Original Assignee
Fidia Advanced Biopolymers S.R.L.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08BPOLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/006Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
    • C08B37/0084Guluromannuronans, e.g. alginic acid, i.e. D-mannuronic acid and D-guluronic acid units linked with alternating alpha- and beta-1,4-glycosidic bonds; Derivatives thereof, e.g. alginates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K8/00Cosmetics or similar toilet preparations
    • A61K8/02Cosmetics or similar toilet preparations characterised by special physical form
    • A61K8/04Dispersions; Emulsions
    • A61K8/042Gels
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K8/00Cosmetics or similar toilet preparations
    • A61K8/18Cosmetics or similar toilet preparations characterised by the composition
    • A61K8/72Cosmetics or similar toilet preparations characterised by the composition containing organic macromolecular compounds
    • A61K8/73Polysaccharides
    • A61K8/733Alginic acid; Salts thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K8/00Cosmetics or similar toilet preparations
    • A61K8/18Cosmetics or similar toilet preparations characterised by the composition
    • A61K8/72Cosmetics or similar toilet preparations characterised by the composition containing organic macromolecular compounds
    • A61K8/73Polysaccharides
    • A61K8/735Mucopolysaccharides, e.g. hyaluronic acid; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0014Skin, i.e. galenical aspects of topical compositions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • A61K9/4866Organic macromolecular compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION, OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS, OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS, OR SURGICAL ARTICLES
    • A61L15/00Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
    • A61L15/16Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
    • A61L15/42Use of materials characterised by their function or physical properties
    • A61L15/60Liquid-swellable gel-forming materials, e.g. super-absorbents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION, OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS, OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS, OR SURGICAL ARTICLES
    • A61L17/00Materials for surgical sutures or for ligaturing blood vessels ; Materials for prostheses or catheters
    • A61L17/14Post-treatment to improve physical properties
    • A61L17/145Coating
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION, OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS, OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS, OR SURGICAL ARTICLES
    • A61L27/00Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/28Materials for coating prostheses
    • A61L27/34Macromolecular materials
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION, OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS, OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS, OR SURGICAL ARTICLES
    • A61L29/00Materials for catheters, medical tubing, cannulae, or endoscopes or for coating catheters
    • A61L29/08Materials for coatings
    • A61L29/085Macromolecular materials
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILET PREPARATIONS
    • A61Q19/00Preparations for care of the skin
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08BPOLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/006Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
    • C08B37/0063Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
    • C08B37/0072Hyaluronic acid, i.e. HA or hyaluronan; Derivatives thereof, e.g. crosslinked hyaluronic acid (hylan) or hyaluronates

Abstract

A polysaccharide hydrogel material consisting of a crosslinked product of a functionalized derivative of alginic acid or hyaluronic acid, whose carboxylic groups are partially esterified with an unsaturated aliphatic or an araliphatic alcohol, and the remaining carboxylic groups are partially salified with an alkaline, alkaline earth metal cation or with tetralkylammonium. This hydrogel material, which is prepared by treatment with radiations selected from UV, β and gamma radiations is advantageously used in medicine, surgery, cosmetics and for the preparation of health care products.

Description

A POLYSACCHARIDE HYDROGEL MATERIAL, A PROCESS FOR ITS PREPARATION AND ITS USE IN MEDICINE, SURGERY, COSMETICS AND FOR THE PREPARATION OF HEALTH CARE PRODUCTS.

FIELD OF THE INVENTION The present invention concerns a polysaccharide hydrogel material consisting of a crosslinked product of a functionalized derivative of alginic acid or hyaluronic acid, a process for its preparation and its use in medicine, surgery, cosmetics and for the preparation of health care products. TECHNOLOGICAL BACKGROUND

Hydrogel materials such as those obtained starting from synthetic polymers such as poly-hydroxy-ethyl-methacrylate (PHEMA) (Holly, F. J. et al., J. Biomed. Mater. Res. 9. 3 5. 1975). or from semisynthetic derivatives of natural polysaccharides such as the crosslinked hyaluronic acid derivative with vinyl-sulfone (Balazs, E. A. et al.,

Blood Coagulation and Fibrinolysis, 1991. 2, I73-I78) are used for preventing surgical adherence, in the release of drugs or biologically active proteins, and in tissue repair. It is also known that hydrogels can be obtained from synthetic polymers by ultraviolet radiation (Amarpreet S. Sawhney et al., Macromolecules, 1993. 26, 581 87). or from hyaluronic acid or chondroitin sulfate (Matsuda et al., ASAJO

Journal 1992, Slide Forum 3 - Innovations I, 154-157), and these are suitable for use in numerous biomedical applications such as drug release or antiadherence. SUMMARY OF THE INVENTION

Subject of the present invention is a polysaccharide hydrogel material consisting of a crosslinked product of a functionalized derivative of alginic acid or hyaluronic acid, whose carboxylic groups are partially esterified with an unsaturated aliphatic or an araliphatic alcohol, and the remaining carboxylic groups are partially salified with a cation selected from the group consisting of alkaline, alkaline earth metal cation or with tetralkylammonium. A further subject of the present invention is the process for preparing said hydrogel material, which comprises subjecting said functionalized hyaluronic or alginic acid optionally dissolved in an aqueous solution to radiations selected from the group consisting of UV, gamma and β radiations, optionally in the presence of a catalyst. The present invention further relates to the use of said hydrogel material in medicine, surgery and in the preparation of health care products in the form of fibers , membranes, threads, gauzes, sponges. These hydrogel materials according to the present invention may also be advantageously used as supports for human cell growth, or as coating for blood vessels, artificial organs, and biomedical materials consisting of polymers such as polyurethanes, polypropylene, polyesters etc.

A further subject of the present invention relates to controlled release medicaments, suitable to be administered by oral, topical, intravenous, intramuscular, or subcutaneous route, containing at least one active principle principle and ,as the vehicle, the polysaccharide hydrogel material according to the present invention. Finally the present invention further relates to cosmetic compositions containing the hydrogel materials according to the present invention.

BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1 shows :

No . 1 : the hydrogel material consisting of the crosslinked product of the hyaluronic acid functionalized derivative with 0 % of carboxylic groups esterified with 3-buten-l-ol and 50% of carboxylic group salified with sodium, prepared as described in Example 1 ,

No. : the hyaluronic acid inner esters (ACP)

No .3 : viscous solution of hyaluronic acid outer esters (HYAFF) No.4 : solution of hyaluronic acid sodium salt .

DETAILED DESCRIPTION OF THE PRESENT INVENTION

The new derivatives according to the present invention present a completely different physical structure from that of the previously described products , such as hyaluronic acid ( European patent No . 0138572) , its inner esters (European patent application No . 0341745) - or outer esters (US patent No. 4 ,851 ,521) as reported in Figure 1. In particular, the difference between the two hydrogels indicated as No . s

1 and 2 is evident . Indeed, while the gels constituted by inner esters of hyaluronic acid (No . 2) are formed by icroparticles of crosslinked polymers bound together by simple , physical-type bonds , the new compounds (No . 1 ) present a compact , three-dimensional structure

(wall-to-wall) . The latter are, therefore, characterised by greater mechanical resistance .

The precursors of the polysaccharide hydrogel materials according to the present invention , namely the functionalized derivatives of hyaluronic or alginic acid whose carboxylic groups are partially esterified with an unsaturated aliphatic or an araliphatic alcohol, and the remaining carboxylic groups are partially salified with a cation selected from the group consisting of alkaline , earth alkaline metal cation or with tetralkylammonium a second part salified with alkaline or alkaline earth metals or quaternary ammonium salts are described in USP 4 , 851 , 521 and in EP 2 1905 respectively . Preferably the hydrogel materials according to the present invention are the crosslinked product of functionalized derivatives of hyaluronic or alginic acid, whose carboxylic groups are partially esterified with aliphatic alcohols such as allyl alcohol , allyl carbinol , 5~hexene-l- ol , or with araliphatic alcohols such as cinnamyl alcohol and 4- benzyloxy-2-butene- l-ol and the remaining carboxylic groups are salified with sodium.

The preferred hydrogel materials according to the present invention are the crosslinked product of the functionalized derivatives of hyaluronic acid.

In this case said hyaluronic acid functionalized derivatives are prepared as described in the above mentioned USP 4 , 851 , 521 by using as starting material a hyaluronic acid having any molecular weight between 400 and 3 , 000 , 000 Dal tons , preferably between 150 , 000 and 1.000, 000 Dal tons .

Particularly preferred hydrogel materials according to the present invention are the crosslinked products of functionalized derivatives of hyaluronic or alginic acid , wherein 75% of the carboxylic groups are esterified with the above mentioned aliphatic or araliphatic unsaturarated alcohols and the remaining 2 % of carboxylic groups are salified with sodium . Other particularly preferred hydrogel materials according to the present invention are the crosslinked products of functionalized derivatives of hyaluronic acid wherein 50% of the carboxylic groups are esterified with the above mentioned aliphatic or araliphatic unsaturated alcohols and the remaining 50% of carboxylic groups are salified with sodium. The process according to the present invention may be carried out in the presence or in the absence of an aqueous solution. By the term aqueous solution we mean: purified water, buffers or physiological solutions, such as phosphate buffer or saline solution. When the reaction is carried out in an aqueous solution of said h aluronic or alginic acid derivative, possible concentrations range between 0.01 and 20% (w/w) , and more preferably between 0.1 and 15% ( /w) .

When the process is carried out in the presence of a catalyst, this is preferably non-toxic radicalic initiator compounds such as 2,2- dimethoxy-2-phenyl acetophenone or benzoin methyl ether. The exposure time to radiation, in the process according to the present invention should be comprised between 5 minutes and 6 hours, and preferably between 10 and 3 0 minutes. It has generally been found that by increasing the concentration of the ester derivative of hyaluronic acid it is possible to obtain the formation of gels after shorter exposure to ultraviolet radiation. The type of aqueous solution used to obtain hydrogels notably affects the viscoelastic properties of these materials, because they belong to the group of polyelectrolytes. As the synthesized gels are derived from a natural polysaccharide matrix, they belong to the class of compounds with bioplastic and pharmaceutical properties, and as above pointed out they can be used in numerous fields, from cosmetics to surgery and medicine. For example, they can be used as films and membranes in various sectors of medicine, such as ophthalmology, dermatology, otorhinolaryngology, neurology, internal and cardiovascular surgery in particular as tissue substitutes and as agents to enable the adhesion of tissue surfaces (such as severed nerves) or in preventing surgical adherence, when used in the form of fibers or threads they are particularly suitable for surgical suture or, when made into gauzes, they can be used to advantage for wound dressings and finally , when made into sponges, they can be advantageously used for the medications of wounds and various lesions.

As above pointed out they can also be advantageously used as supports of human cells such as keratinocytes, fibroblasts, osteocytes, chondrocytes, urocytes, stem cells, endothelial cells, Kupfer's and Langerhan's cells . Moreover as above explained they can be advantageously utilized as coating for organs, such as cardiac valves, or blood vessels, or of biomedical articles such as urologic cathethers. As a matter of fact this type of coating improves to a high degree the biocompatibility of the article to be grafted, thereby improving the performance thereof at a biological level. In particular the hydrogel materials are used as coating for blood vessels following coronary angioplasty, in repair following the dissection of blood vessels and the attachment of flaps on the walls of the same, following spontaneous detachment or lesion, and in the sealing of aneurisms. Therefore a further subject of the present invention relates to the process for coating these blood vessels, artificial organs or biomedical articles, which comprises the following steps: a) applying a layer of these hyaluronic or alginic functionalized derivatives as such or in the form of an aqueous solution, by means of conventional techniques onto the surface of these blood vessels, artificial organs or biomedical articles, b) subjecting the articles to radiations selected from the group consisting of UV, beta or gamma radiation, optionally in the presence of catalysts.

In addition the hydrogel material according to the present invention can be advantageously used as agents to enable cell-cell interactions and cell-polymer interaction, as they can act as material for cell recruitment, as fillers in replacements for example in breast replacements, as fillers for dental cavities and in cosmetic surgery, as fillers, in place of collagen, for small areas or cavities and in soft tissue. Furthermore, as above seen the hydrogel materials according to the present invention can be advantageously used as the vehicle in controlled release medicaments. These medicaments can be in particular administered by oral, topical, intravenous, intramuscular, or subcutaneous route. The active principles contained in this medicament are preferably anaesthetic, analgesic, antiinflammatory, vasocontrictor, antibiotic/ antibacterial or antiviral agents, proteins, peptides, growth factor enzymes or mixtures thereof. Further subjects of the present invention therefore relate to the alternative processes for preparing these medicaments.

The first process encompasses the incorporation of the active principle in the gel by swelling said hydrogel in a dry state in an aqueous solution containing this active principle.

In the second process the incorporation of the active principle in the hydrogel material, according to the present invention, comprises mixing the active principle into the solution of said functionalized hayluronic or alginic acid derivative and then radiating it to obtain a gel. This last method is particularly useful when large molecules are to be incorporated, such as peptides, proteins, growth factors and enzymes, which would find it difficult to penetrate into a gel left to swell in aqueous solution. In particular when this medicament is administered by topical or oral route, it is preferably in the form of a gel.

In particular when the medicaments according to the present invention are administered by the subcutaneous, intramuscular or intravenous route, are preferably in the form of viscoelastic solutions. The medicaments, according to the present invention, when administered by the subcutaneous route, can also be in the form of capsules. Finally these medicaments, when subcutaneously, intravenously or intramuscularly administered, may also be in the form of microcapsules or microspheres. The cosmetic compositions according to the present invention are preferably in the form of creams.

For purely descriptive purposes, and without being limited to the same, we report hereafter some examples of the preparation of the hydrogels according to the present invention: EXAMPLE 1: Preparation of a hydrogel, from a derivative of hyaluronic acid with 5 % of its carboxylic functions esterified with 3-butene-l- ol alcohol (allyl carbinol, and the remaining 50 salified with sodium 6.21 gr of tetrabutylammonium salt of hyaluronic acid with a molecular weight of 180,000 Daltons (10 meq) ( USP4.851,521) is solubilized in

248 ml of dimethylsulfoxide (DMS0) at room temperature. To this solution is added 0.675 g of 4-bromo-l-butene (5 meq) and the solution is left to stand at a temperature of 30°C for 24 hours. A 2.5% solution (w/w) of NaCl in water is then added and the resulting mixture is poured into 750 ml of acetone, stirring the while. A precipitate is formed which is filtered and washed three times in 100 ml of acetone/water 5:1. three times with 100 ml of acetone and then vacuum-dried for 24 hours at 30°C. 4.17 gr of the desired product are thus obtained. Quantitative determination of the allyl carbinol content is performed by gas chromatography after alkaline hydrolysis.

The total content of ester groups is conducted in accordance with the saponification method described on pages 169-172 of "Quantitative organic analysis via functional groups", IV Ed., John Wiley and Sons Publication. The ester derivative thus obtained is solubilized at room temperature in purified water at a concentration of 100 mg/ml (300 mg of product in 3 ml) . The solution is supplemented with 10 microliters of radicalic initiator, while being stirred. The radicalic initiator solution is prepared by dissolving 100 mg of 2,2-dimethoxy-2-phenyl acetophenone (ALDRICH) in 0.5 ml of 2-pyrrolidone. The mixture is divided into equal aliquots of 1 ml each and placed in 5-ml china crucibles. The material thus preprepared is exposed to ultraviolet radiation (336" nm) , using a portable UV lamp, CAMAG model (220v; O.lδA) or a UV lamp Triwood lamp 6/36 sold by Helios Italquartz R Exposure time is 30 minutes.

EXAMPLE 2: Preparation of hydrogel, from a functionalized derivative of a hyaluronic acid, with 2 of its carboxylic functions esterified with 5"bexene-l-ol alcohol and the remaining 75 salified with sodium

6.21 gr of tetrabutylammonium salt of hyaluronic acid with a molecular weight of 180,000 Daltons (10 meq) (US 4,851,521) , optionally dissolved in an aqueous solution, is solubilized in 248 ml of dimethylsulfoxide (DMS0) at room temperature. To this solution is added 0.407 gr of 6-bromo-l-hexene (2.5 meq) and the solution is left to stand at a temperature of 30°C for 24 hours. A 2.5% solution (w/w) of NaCl in water is then added and the resulting mixture is poured into 750 ml of acetone, stirring the while. A precipitate is formed which is filtered and washed three times in 100 ml of acetone/water 5:1, three times with 100 ml of acetone and then vacuum-dried for 24 hours at 30°C. 4.16 gr of the desired product is thus obtained. Quantitative determination of the 5-hexene-l-ol content is performed by gas chromatography after alkaline hydrolysis. The total content of ester groups is conducted in accordance with the saponification method described on pages 169-172 of "Quantitative organic analysis via functional groups", IV Ed., John Wiley and Sons Publication. The ester derivative thus obtained is solubilized at room temperature in purified water at a concentration of 150 mg/ml (450 mg of product in 3 ml of water) . The solution is supplemented while stirred with 10 microliters of radicalic initiator, prepared as in Example 1. The mixture is divided into equal aliquots of 1 ml each and placed in 5ml china crucibles. The material is exposed to ultraviolet radiation as in Example 1, for an exposure time of 20 minutes.

EXAMPLE 3= Preparation of a hydrogel, from a functionalized derivative of hyaluronic acid with 50% of its carboxylic functions esterified with cinnamyl alcohol (CgH,-CH=CH-CH2-0H) and the remaining 50% salified with sodium

6.21 gr of tetrabutylammonium salt of hyaluronic acid with a molecular weight of 180,000 Daltons (10 meq) (USP 4,851,521) is solubilized in 248 ml of dimethylsulfoxide (DMSO) at room temperature. To this solution is added O.985 gr of cinnamyl bromide (5 meq) and the solution is left to stand at a temperature of 30°C for 24 hours. A

2.5% solution (w/w) of NaCl in water is then added and the resulting mixture is poured into 750 ml of acetone, stirring the while. A precipitate is formed which is filtered and washed three times in 100 ml of acetone/water 5:1. three times with 100 ml of acetone and then vacuum-dried for 24 hours at 30°C. 4.48 gr of the desired product is thus obtained. Quantitative determination of the cinnamyl alcohol content is performed by gas chromatography after alkaline hydrolysis. The total content of ester groups is conducted in accordance with the saponification method described on pages 169-172 of "Quantitative organic analysis via functional groups", IV Ed., John Wiley and Sons

Publication. The ester derivative thus obtained is solubilized at room temperature in purified water at a concentration of 100 mg/ml (300 mg of product in 3 ml of water) . The solution is supplemented with 10 microliters of radicalic initiator. The radicalic initiator solution is prepared by dissolving 100 mg of benzoin methyl ether (ALDRICH) in 0.5 ml of 2pyrrolidone. The mixture is divided into equal aliquots of 1 ml each and placed in 5-ml china crucibles. The material is exposed to ultraviolet radiation as in Example 1, for an exposure time of 30 minutes. EXAMPLE 4: Preparation of a hydrogel, from a functionalized derivative of alginic acid with 0 of its carboxylic functions esterified with 3-butene-l-ol alcohol (allyl carbinol, and the remaining 0% salified with sodium 4.17 gr of tetrabutylammonium salt cf alginic acid (prepared with alginic acid from Macrocystis pyrifera) corresponding to 10 meq of a monomeric unit (Italian patent by Fidia S.p.A., No. 1203814) is solubilized in 248 ml of dimethylsulfoxide (DMSO) at room temperature. To this solution is added 0.675 gr of 4-bromo-l-butene (5 meq) and the solution is left to stand at a temperature of 30°C for 24 hours. A 2.5% solution (w/w) of NaCl in water is then added and the resulting mixture is poured into 7 0 ml of acetone, stirring the while. A precipitate is formed which is filtered and washed three times in 100 ml of acetone/water :1. three times with 100 ml of acetone and then vacuum-dried for 24 hours at 30°C. 2.14 gr of the desired product is thus obtained. Quantitative determination of the allyl carbinol content is performed by gas chromatography after alkaline hydrolysis. The total content of ester groups is conducted in accordance with the saponification method described on pages 16 -172 of "Quantitative organic analysis via functional groups", IV Ed., John Wiley and Sons Publication. The ester derivative thus obtained is solubilized at room temperature in purified water at a concentration of 100 mg/ml (300 mg of product in 3 nil of water) . The solution is supplemented with 10 microliters of radicalic initiator, prepared as in Example 1. The mixture is divided into equal aliquots of 1 ml each and placed in 5-ml china crucibles. The material is exposed to ultraviolet radiation as in Example 1, for an exposure time of 30 minutes. EXAMPLE : Preparation of a membrane of a hydrogel from a functionalized derivative , with 50% of its carboxylic functions esterified with cinnamyl alcohol and the remaining 50% salified with sodium 6.21 gr of tetrabutylammonium salt of hyaluronic acid with a molecular weight of 180,000 Daltons (10 meq) (USP4.851.521) , is solubilized in 248 ml of dimethylsulfoxide (DMSO) at room temperature. To this solution is added O.985 gr of cinnamyl bromide (5 meq) and the solution is left to stand at a temperature of 30°C for 24 hours. A 2.5% solution (w/w) of NaCl in water is then added and the resulting mixture is poured into 750 ml of acetone, stirring the while. A precipitate is formed which is filtered and washed three times in 100 ml of acetone/water 5"-l, three times with 100 ml of acetone and then vacuum-dried for 24 hours at 30°C. 4.48 gr of the desired product is thus obtained. Quantitative determination of the cinnamyl alcohol content is performed by gas chromatography after alkaline hydrolysis. The total content of ester groups is conducted in accordance with the saponification method described on pages 169-172 of "Quantitative organic analysis via functional groups", IV Ed., John Wiley and Sons Publication. The ester derivative thus obtained is solubilized at room temperature in purified water at a concentration of 100 mg/ml (1 g in 10 ml of water) . The solution is supplemented, while stirring, with 35 microliters of radicalic initiator, prepared as in Example 1. The mixture is spread evenly over glass slides measuring 5cm . The material is then exposed to ultraviolet radiation (336 nm) , using a portable UV lamp, CAMAG model (2230v; O.lδA), for an exposure time of

2 hours. EXAMPLE 6: Preparation of a cream containing as active principle the hydrogel of Example 3 based on hyaluronic acid partially esterified with cinnamyl alcohol

A hydrogel prepared according to Example 3 is dried for 48 hours at

37°C and at 60° for 24 hours, after which it was crushed and sieved through a 40-100 micron mesh.

100 gr of cream contain: dry state hydrogel prepared as described in Ex.3 0.1 g

Polyethylene monostearate 400 10 g

Cetiol V 5 g Lanette SX 2 g

Methyl paraoxybenzoate 0.075 g

Propyl paraoxybenzoate 0.050 g

Sodium dihydroacetate 0.100 g

Glycerine 1 .500 g Sorbitol 70 1 .500 g

Test cream 0.050 g

Sterile water q.s. to 100 ml

EXAMPLE "J : Preparation of an injectable solution containing as its active principle a hydrogel based on hyaluronic acid esterified with cinnamyl alcohol prepared as described in Example 3 One 100-ml ampoule contains: dry state hydrogel prepared as described in Ex.3 0.1 g Sodium chloride 0.9 g

Sterile water q.s. to 100 ml EXAMPLE 8: Preparation of a gelatin capsule containing the hydrogel and carbene oxolone

The hydrogels described in Examples 1-3 are cut (1 cπ ) and dried for

48 hours at 37°C and at for 24 hours at 6θcC. The compounds thus dried are left to swell for 24 hours at 37°C in a solution of carbenoxolone at a concentration of 50 mg/ml. These processes of drying and drug incorporation were repeated four times on some of the gel samples.

This was to increase the quantity of incorporated active principle.

The present example also refers to the loading of active principles or drugs other than the one mentioned here. EXAMPLE Preparation of a hydrogel, with 50% of its carboxylic functions esterified with 3_butene-l-ol alcohol (allyl carbinol, CH2=

CH-(CH2)2"0H) and the remaining 50% salified with sodium, by exposure to gamma radiations, in the presence of a radicalic initiator. The derivative prepared as described in the first part of Example 1, is solubilized at room temperature in purified water at a concentration of 100 mg/ml (300 mg of product in _ ml water). The solution is supplemented with 10 microliters of a radicalic initiator, while being stirred. This solution is prepared by dissolving 100 mg 2,2 -dimethoxy-2-phenylacetophenone in 0.5 ml of vinyl-2-pyrrolidone.

The mixture is placed in a 5 ml glass vial selaed with a stopper and fastened with a metal cap . The material thus prepared undergoes gamma radiations at 0.09 Mrad/hr for 4 hours.

EXAMPLE 10 Preparation of a hydrogel from a functionalized derivative of hyaluronic acid, with 25% of carboxylic functions esterified with 3-hexene-l-ol alcohol (CH2=CH-(CH2)_-0H) and the remaining 75% salified with sodium by exposure to gamma rays in the absence of a radicalic initiator.

The functionalized derivative of hyaluronic acid prepared as described in Example 2, is solubilized at room temperature in purified water at a concentration of 1 0 mg/ml (450mg of product in 3 ml water) . The mixture is placed in a 5 ml glass vial sealed with a stopper and fastened with a metal cap. The material thus prepared undergoes gamma radiations at 1.25 Mrad/hr for 2 hours.

EXAMPLE 11 - Preparation of a hyaluronic acid hydrogel membrane , from a functionalized hyaluronic acid derivative wherein 0% of its carboxylic functions are esterified with 3-butene-l-ol alcohol (allyl carbinol, and the remaining 50% salified with sodium, by exposure to gamma radiations in the absence of a radicalic initiator. The functionalized derivative of hyaluronic acid, prepared as described in Example 1, is solubilized at room temperature in purified water at a concentration of 60 mg/ml (600 mg product in 10 ml

2 water) .The solution is spread evenly over a cm glass slide and left to evaporate spontaneously at 37°C. The membranes thus obtained undergo gamma radiation at 2.5 Mrad/hr for 2 hours. EXAMPLE 12 Preparation of a hydrogel from a functionalized derivative of hyaluronic acid, whose 25% of carboxylic functions are esterified with 3-hexene-l-ol alcohol and the remaining 75% are salified with sodium by exposure to beta rays in the presence of a radicalic initiator.

The functionalized derivative prepared as decribed in example 2, is solubilized at room temperature in purified water at a concentration of 80 mg/ml (240 mg product in 3 ml water) . The solution is supplemented with 10 microliters of the radicalic initiator prepared as described in Example 9- The mixture is placed in a 5 ml glass vial sealed with a stopper and fastened with a metal cap. The material thus prepared undergoes beta radiation at 0.15 KGy.

EXAMPLE 13 : Preparation of a hydrogel membrane , from a functionalized derivative of hyaluronic acid derivative, wherein 50% of carboxylic functions are esterified with 3-butene-l-ol alcohol (allyl carbinol, CR^CH-.C^^-OH) and the remaining 50% salified with sodium by exposure to beta rays in the absence of a radicalic initiator. The material is prepared according to example 11 and the membranes thus obtained undergo beta radiation at 2.5 KGy.

Claims

CLAIMS 1. A polysaccharide hydrogel material consisting of a crosslinked product of a functionalized derivative of hyaluronic or alginic acid, whose carboxylic groups are partially esterified with an unsaturated aliphatic or an araliphatic alcohol, and the remaining carboxylic groups are partially salified with a cation selected from the group consisting of alkaline, alkaline earth metal cation or with tetralkylammonium. 2. The polysaccharide hydrogel material according to claim 1, wherein they are the crosslinked product of functionalized derivatives of hyaluronic or alginic acid, whose carboxylic groups are partially esterified with aliphatic alcohols selected from the group consisting of allyl alcohol, allyl carbinol, 5-hexene-l-ol, or with araliphatic alcohols such as cinnamyl alcohol and 4-benzyloxy-2- butene-1-ol and the remaining carboxylic groups are salified with sodium cation. 3- The polysaccharide hydrogel material according to any one of claims 1 and 2 wherein they are the crosslinked product of the functionalized derivatives of hyaluronic acid, having a molecular weight ranging from 150,000 and 1,000,000 Daltons. 4. The polysaccharide hydrogel material according to any one of claims 1-3. wherein they are the crosslinked products of functionalized derivatives of hyaluronic or alginic acid having 75% of the carboxylic groups are esterified with aliphatic or araliphatic unsaturarated alcohols and the remaining 25% of carboxylic groups are salified with sodium. 5- The polysaccharide hydrogel material according to any one of claims 1-3, wherein they are the crosslinked products of functionalized derivatives of hyaluronic acid having 50 % of the carboxylic groups esterified with the above mentioned aliphatic or araliphatic unsaturarated alcohols and the remaining 50% of carboxylic groups salified with sodium. 6. A process for preparing the polysaccharide hydrogel material according to any one of claims 1-4 which comprises subjecting said functionalized hyaluronic or alginic acid optionally dissolved in an aqueous solution to radiations selected from the group consisting of UV, gamma and β radiations, optionally in the presence of a catalyst. 7- The process according to claim 6 wherein when it is carried out on an aqueous solution of said hyaluronic or alginic acid derivative, the concentration of said functionalized derivative of alginic or hyaluronic acid ranges between 0.01 and 20% (w/w). 8. The process according to claim 7 wherein said concentration of said functionalized derivative of hyaluronic or alginic in the aqueous solution range between 0.1 and 15% (w/w). 9- The process according to any one of claims 6-8, wherein, when the process is carried out in the presence of a catalyst this is a non- toxic radicalic initiator selected from the group consisting of 2 ,2- dimethoxy-2-phenyl acetophenone or benzoin methyl ether. 10. The process according to any one of claims " - 10 with exposure time to radiation comprised between 5 minutes and 6 hours. 11 . The process according to claim 10 wherein said exposure times are comprised between 10 and 360 minutes. 12. The polysaccharide hydrogel material according to any one of claims 1-5, in the form of fibers , membranes, threads, gauzes, sponges for use in medicine, surgery, and in the preparation of health care products. 13. The polysaccharide hydrogel material according to claim 12, in the form of films and membranes for use in ophthalmology, dermatology, otorhinolaryngology, neurology, internal and cardiovascular surgery as tissue substitutes, as agents to enable the adhesion of tissue surfaces or in preventing surgical adherence. 14. The polysaccharide hydrogel material according to claim 12, in the form of fibers or threads for surgical suture. 15. The polysaccharide hydrogel material according to claim 12 in the form of gauzes for wound dressings. 16. The polysaccharide hydrogel material according to claim 12 in the form of sponges for use in medications of wounds and various lesions. 17. The polysaccharide hydrogel material according to any one of claims 1-5, for use as the support of human cells selected from the group consisting of keratinocytes , fibroblasts, osteocytes, chondrocytes, urocytes, stem cells, endothelial cells, Kupfer's and Langerhan's cells . 18. Coating consisting of the polysaccharide hydrogel material according to any one of claims 1-5 for blood vessels, artificial organs, and biomedical materials consisting of polymers selected from the group consisting of polyurethanes, polypropylene, polyesters. 19. The coating according to claim 18, wherein said artificial organs are cardiac valves and said biomedical articles are urologic catheters. 20. The coating according to claim lδ for blood vessels following coronary angioplasty, in repair following the dissection of blood vessels and the attachment of flaps on the walls of the same , following spontaneous detachment or lesion, and in the sealing of aneurisms . 21. A process for applying the coating according to any one of claims lδ-20 onto blood vessels , artificial organs and biomedical articles comprising the following steps: a) applying a layer of these hyaluronic or alginic functionalized derivatives as such or in the form of an aqueous solution, by means of conventional techniques onto the surface of said blood vessels, artificial organs or biomedical articles, b) subjecting said articles to radaition selected from the group consisting of UV, beta or gamma radiation, optionally in the presence of a catalyst. 22. The polysaccharide hydrogel material according to any one of claims 1-5 for use as agents to enable cell-cell interaction and cell- polymer interaction. 23. The polysaccharide hydrogel material according to any one of claims 1-5. for use as fillers in replacements, and in dental cavities. 24. The hydrogel material according to claim 23, wherein said replacement is breast replacement. 25. The hydrogel material according to any one of claims 1-5 for use in cosmetic surgery as fillers for small areas or cavities and in soft tissue . 26. A controlled release medicament, suitable to be administered by oral , topical , intravenous , intramuscular , or subcutaneous route containing at least one active principle and , as the vehicle , the polysaccharide hydrogel material according to any one of claims 1-3. 27. The controlled release medicament according to claim 26, wherein said active principle is selected from the group consisting of anaesthetic, analgesic, antiinflammatory, vasocontrictor, antibiotic/ antibacterial or antiviral agents, proteins, peptides, growth factor enzymes and mixtures thereof. 2δ. The controlled release medicament according to any one of claims 26 and 27, wherein, when this medicament is administered by topical or oral route, it is in the form of a gel. 29. The controlled release medicament according to any one of claims 26 and 27 for subcutaneous, intramuscular or intravenous administrations in the form of a viscoelastic solution. 30. The medicament according to any one of claims 26 and 27 for subcutaneous administration in the form of capsules. 31- The medicament according to any one of claims 26 and 27 , for subcutaneous, intravenous or intramuscular administration in the form of microcapsules or microspheres. 32. A process for preparing a controlled release medicament according to any one of claims 26-31, wherein the incorporation of the active principle in the hydrogel material is accomplished by swelling this hydrogel material in a dry state in an aqueous solution containing this active principle. 33- A process for preparing the controlled release medicament according to any one of claims 26-31, wherein the incorporation of the active principle in the hydrogel material comprises mixing the active principle into the solution of said functionalized hyaluronic or alginic acid derivative and then treating the obtained mixture with radiation selected from the group consisting of: UV, beta and gamma radiations, optionally in the presence of a catalyst. 34. The process for preparing controlled release medicament according to claim 33. wherein the active principle is selected from the group consisting of proteins, peptides, growth factors, and enzymes. 35- A cosmetic composition containing the polysaccharide hydrogel material according to any one of claims 1-5. 36. The cosmetic composition according to claim 35 in the form of a cream.
PCT/EP1996/002270 1995-05-22 1996-05-22 A polysaccharide hydrogel material, a process for its preparation and its use in medicine, surgery, cosmetics and for the preparation of health care products WO1996037519A1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
ITPD950101 1995-05-22
ITPD95A000101 1995-05-22

Publications (1)

Publication Number Publication Date
WO1996037519A1 true true WO1996037519A1 (en) 1996-11-28

Family

ID=11391062

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP1996/002270 WO1996037519A1 (en) 1995-05-22 1996-05-22 A polysaccharide hydrogel material, a process for its preparation and its use in medicine, surgery, cosmetics and for the preparation of health care products

Country Status (1)

Country Link
WO (1) WO1996037519A1 (en)

Cited By (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997018842A1 (en) * 1995-11-20 1997-05-29 Fidia Advanced Biopolymers S.R.L. A biologic material comprising an efficient culture of bone marrow stem cells partially or completely differentiated into connective tissue cells and a three-dimensional biocompatible and biodegradable matrix consisting of a hyaluronic acid derivative
WO1998056897A1 (en) * 1997-06-11 1998-12-17 Fidia Advanced Biopolymers S.R.L. Hyaluronic acid derivative based cell culture and biodegradable three-dimensional matrix
WO1999024070A2 (en) * 1997-11-06 1999-05-20 Fidia Advanced Biopolymers, S.R.L. Ester derivatives of hyaluronic acid with viscoelastic properties and their use in the biomedical and healthcare field
FR2793693A3 (en) * 1999-05-18 2000-11-24 Martine Bulette Vascular prosthesis is made of base material, optionally textile, impregnated with bio-polymer of vegetable origin to make it impermeable to blood
WO2001046265A1 (en) * 1999-12-22 2001-06-28 Genzyme Corporation Water insoluble derivatives of polyanionic polysaccharides
WO2001056404A1 (en) * 2000-02-03 2001-08-09 Kbp Co., Ltd. Low molecular weight polymannuronate
FR2811671A1 (en) * 2000-07-17 2002-01-18 Corneal Ind Hydrogel polymer (s), resistant to biodegradation, preparation and use as tissue regeneration medium
WO2003061626A1 (en) * 2002-01-18 2003-07-31 Control Delivery Systems, Inc. Polymeric gel system for the controlled delivery of codrugs
WO2003076475A1 (en) * 2002-03-12 2003-09-18 Fidia Advanced Biopolymers S.R.L. Ester derivatives of hyaluronic acid for the preparation of hydrogel materials by photocuring
US6900188B2 (en) * 1998-07-31 2005-05-31 Les Laboratories Brothier System for treating wounds and method for producing this system
WO2006002528A1 (en) * 2004-06-30 2006-01-12 Covalon Technologies Inc. Non-adhesive hydrogels
US7332179B2 (en) 2003-12-12 2008-02-19 Kimberly-Clark Worldwide, Inc. Tissue products comprising a cleansing composition
US7642395B2 (en) 2004-12-28 2010-01-05 Kimberly-Clark Worldwide, Inc. Composition and wipe for reducing viscosity of viscoelastic bodily fluids
WO2011132800A1 (en) 2010-04-22 2011-10-27 帝人株式会社 Hydrogel
EP2429496A1 (en) * 2009-05-14 2012-03-21 Central Michigan University Composition and method of preparation of polysaccharide gel-based artificial, biodegradable skin scaffolds
US8367109B2 (en) * 2008-04-09 2013-02-05 Brookhaven Science Associates, Llc Microbes encapsulated within crosslinkable polymers
US9228027B2 (en) 2008-09-02 2016-01-05 Allergan Holdings France S.A.S. Threads of Hyaluronic acid and/or derivatives thereof, methods of making thereof and uses thereof

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0251905A2 (en) * 1986-06-30 1988-01-07 FIDIA S.p.A. Esters of alginic acid
EP0265116A2 (en) * 1986-10-13 1988-04-27 FIDIA S.p.A. Cross-linked esters of hyaluronic acid
WO1993009176A2 (en) * 1991-10-29 1993-05-13 Clover Consolidated, Limited Crosslinkable polysaccharides, polycations and lipids useful for encapsulation and drug release
WO1994001468A1 (en) * 1992-07-03 1994-01-20 M.U.R.S.T., Italian Ministry For Universities And Scientific And Technological Research Hyaluronic acid and derivatives thereof in interpenetrating polymer networks (ipn)

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0251905A2 (en) * 1986-06-30 1988-01-07 FIDIA S.p.A. Esters of alginic acid
EP0265116A2 (en) * 1986-10-13 1988-04-27 FIDIA S.p.A. Cross-linked esters of hyaluronic acid
WO1993009176A2 (en) * 1991-10-29 1993-05-13 Clover Consolidated, Limited Crosslinkable polysaccharides, polycations and lipids useful for encapsulation and drug release
WO1994001468A1 (en) * 1992-07-03 1994-01-20 M.U.R.S.T., Italian Ministry For Universities And Scientific And Technological Research Hyaluronic acid and derivatives thereof in interpenetrating polymer networks (ipn)

Cited By (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6610669B1 (en) 1987-09-18 2003-08-26 Genzyme Corporation Water insoluble derivatives of polyanionic polysaccharides
WO1997018842A1 (en) * 1995-11-20 1997-05-29 Fidia Advanced Biopolymers S.R.L. A biologic material comprising an efficient culture of bone marrow stem cells partially or completely differentiated into connective tissue cells and a three-dimensional biocompatible and biodegradable matrix consisting of a hyaluronic acid derivative
WO1998056897A1 (en) * 1997-06-11 1998-12-17 Fidia Advanced Biopolymers S.R.L. Hyaluronic acid derivative based cell culture and biodegradable three-dimensional matrix
WO1999024070A2 (en) * 1997-11-06 1999-05-20 Fidia Advanced Biopolymers, S.R.L. Ester derivatives of hyaluronic acid with viscoelastic properties and their use in the biomedical and healthcare field
WO1999024070A3 (en) * 1997-11-06 1999-07-15 Fidia Advanced Biopolymers Srl Ester derivatives of hyaluronic acid with viscoelastic properties and their use in the biomedical and healthcare field
US6900188B2 (en) * 1998-07-31 2005-05-31 Les Laboratories Brothier System for treating wounds and method for producing this system
FR2793693A3 (en) * 1999-05-18 2000-11-24 Martine Bulette Vascular prosthesis is made of base material, optionally textile, impregnated with bio-polymer of vegetable origin to make it impermeable to blood
WO2001046265A1 (en) * 1999-12-22 2001-06-28 Genzyme Corporation Water insoluble derivatives of polyanionic polysaccharides
WO2001056404A1 (en) * 2000-02-03 2001-08-09 Kbp Co., Ltd. Low molecular weight polymannuronate
FR2811671A1 (en) * 2000-07-17 2002-01-18 Corneal Ind Hydrogel polymer (s), resistant to biodegradation, preparation and use as tissue regeneration medium
WO2002005753A1 (en) * 2000-07-17 2002-01-24 Corneal Industrie Polymer hydrogel resistant to biodegradation, preparation and use thereof as tissue regeneration support
WO2003061626A1 (en) * 2002-01-18 2003-07-31 Control Delivery Systems, Inc. Polymeric gel system for the controlled delivery of codrugs
WO2003076475A1 (en) * 2002-03-12 2003-09-18 Fidia Advanced Biopolymers S.R.L. Ester derivatives of hyaluronic acid for the preparation of hydrogel materials by photocuring
US8178499B2 (en) 2002-03-12 2012-05-15 Fidia Farmaceutici S.P.A. Ester derivatives of hyaluronic acid for the preparation of hydrogel materials by photocuring
US8178663B2 (en) 2002-03-12 2012-05-15 Fidia Farmaceutici S.P.A. Ester derivatives of hyaluronic acid for the preparation of hydrogel materials by photocuring
US7462606B2 (en) 2002-03-12 2008-12-09 Fidia Farmaceutici S.P.A. Ester derivatives of hyaluronic acid for the preparation of hydrogel materials by photocuring
US7332179B2 (en) 2003-12-12 2008-02-19 Kimberly-Clark Worldwide, Inc. Tissue products comprising a cleansing composition
WO2006002528A1 (en) * 2004-06-30 2006-01-12 Covalon Technologies Inc. Non-adhesive hydrogels
US7642395B2 (en) 2004-12-28 2010-01-05 Kimberly-Clark Worldwide, Inc. Composition and wipe for reducing viscosity of viscoelastic bodily fluids
US8367109B2 (en) * 2008-04-09 2013-02-05 Brookhaven Science Associates, Llc Microbes encapsulated within crosslinkable polymers
US9228027B2 (en) 2008-09-02 2016-01-05 Allergan Holdings France S.A.S. Threads of Hyaluronic acid and/or derivatives thereof, methods of making thereof and uses thereof
US9861570B2 (en) 2008-09-02 2018-01-09 Allergan Holdings France S.A.S. Threads of hyaluronic acid and/or derivatives thereof, methods of making thereof and uses thereof
EP2429496A4 (en) * 2009-05-14 2014-03-26 Anja Mueller Composition and method of preparation of polysaccharide gel-based artificial, biodegradable skin scaffolds
EP2429496A1 (en) * 2009-05-14 2012-03-21 Central Michigan University Composition and method of preparation of polysaccharide gel-based artificial, biodegradable skin scaffolds
WO2011132800A1 (en) 2010-04-22 2011-10-27 帝人株式会社 Hydrogel

Similar Documents

Publication Publication Date Title
Duranti et al. Injectable hyaluronic acid gel for soft tissue augmentation
US4636524A (en) Cross-linked gels of hyaluronic acid and products containing such gels
Lloyd et al. Carbohydrate polymers as wound management aids
US5644049A (en) Biomaterial comprising hyaluronic acid and derivatives thereof in interpenetrating polymer networks (IPN)
Kirker et al. Glycosaminoglycan hydrogel films as bio-interactive dressings for wound healing
US4582865A (en) Cross-linked gels of hyaluronic acid and products containing such gels
US5643464A (en) Process for preparing a sterile, dry crosslinking agent
US6887974B2 (en) Crosslinking agents and methods of use
US6030958A (en) Water insoluble derivatives of hyaluronic acid
US5128326A (en) Drug delivery systems based on hyaluronans derivatives thereof and their salts and methods of producing same
US20100035838A1 (en) Cross-linked polysaccharide gels
US6380154B1 (en) Synthetic proteins for in vivo drug delivery and tissue augmentation
US20050271729A1 (en) Crosslinking hyaluronan and chitosanic polymers
US5166187A (en) Biomaterials with a base of mixtures of collagen, chitosan and glycosaminoglycans, process for preparing them and their application in human medicine
US6831172B1 (en) Cross-linked hyaluronic acids and medical uses thereof
US5827937A (en) Polysaccharide gel composition
US5760200A (en) Water insoluble derivatives of polyanionic polysaccharides
EP0138572B1 (en) Hyaluronic acid fractions having pharmaceutical activity, methods for preparation thereof, and pharmaceutical compositions containing the same
US5876744A (en) Highly bioadhesive and mucoadhesive compositions containing polyvinyl alcohol, polycarbophil and biopolymer for the treatment of skin conditions and as vehicles for active ingredients
US5378472A (en) Methyl pyrrolidinone chitosan, production process and uses thereof
US6579978B1 (en) Biomaterials comprising N-sulphated hyaluronic acid compounds or derivatives thereof
US6387413B1 (en) Hyaluronic acid gel, a method of its production and medical material containing it
US5550187A (en) Method of preparing crosslinked biomaterial compositions for use in tissue augmentation
US5527856A (en) Method of preparing crosslinked biomaterial compositions for use in tissue augmentation
US6586493B1 (en) Polysaccharide-based hydrogels and pre-gel blends for the same

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AL AM AU AZ BB BG BR BY CA CN CZ EE GE HU IS JP KE KG KP KR KZ LK LR LS LT LV MD MG MK MN MW MX NO NZ PL RO RU SD SG SI SK TJ TM TR TT UA UG US UZ VN AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): KE LS MW SD SZ UG AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase